Ie

Applied Molecular Transport to Present at Canaccord Genuity’s 41st Annual Growth Conference

Retrieved on: 
Thursday, August 5, 2021
Biology, GLOBE, Nasdaq, CA, AMTI, Ie, GMP, Autoimmunity, Conference, SAN, AMT, Disease, Pharmaceutical industry

SOUTH SAN FRANCISCO, Calif., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a clinical-stage biopharmaceutical company, today announced that Tahir Mahmood, Ph.D., chief executive officer and co-founder, will participate in a fireside chat during Canaccord Genuitys 41st Annual Growth Conference on Wednesday, August 11, 2021 at 2:30 p.m.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a clinical-stage biopharmaceutical company, today announced that Tahir Mahmood, Ph.D., chief executive officer and co-founder, will participate in a fireside chat during Canaccord Genuitys 41st Annual Growth Conference on Wednesday, August 11, 2021 at 2:30 p.m.
  • A live webcast will be accessible via the Events page of the Applied Molecular Transport website at https://ir.appliedmt.com/news-events/events .
  • About Applied Molecular Transport Inc.
  • Active transport is an efficient mechanism that uses the cells own machinery to transport materials across the IE barrier.

Iterum Therapeutics Receives Complete Response Letter from U.S. Food and Drug Administration for Oral Sulopenem

Retrieved on: 
Monday, July 26, 2021
Food and Drug Administration, United States Public Health Service

Food and Drug Administration(FDA) for its New Drug Application (NDA) for sulopenem etzadroxil/probenecid (oral sulopenem) onJuly 23, 2021.

Key Points: 
  • Food and Drug Administration(FDA) for its New Drug Application (NDA) for sulopenem etzadroxil/probenecid (oral sulopenem) onJuly 23, 2021.
  • The FDA recommended that Iterum conduct at least one additional adequate and well-controlled clinical trial, potentially using a different comparator drug.
  • Iterum Therapeutics is advancing its first compound, sulopenem, a novel penem anti-infective compound, in Phase 3 clinical development with an oral formulation and IV formulation.
  • Iterum Therapeutics has received Qualified Infectious Disease Product (QIDP) and Fast Track designations for its oral and IV formulations of sulopenem in seven indications.

Trinity Biotech Provides A Business Development Update For Q2 2021

Retrieved on: 
Friday, July 16, 2021
Medicine, Branches of biology, Natural sciences, Immunologic tests, Medical tests, Biotechnology, Chromatography, Molecular biology, Rapid antigen test

DUBLIN, Ireland, July 16, 2021 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) provides a business development update for Q2 2021.

Key Points: 
  • DUBLIN, Ireland, July 16, 2021 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) provides a business development update for Q2 2021.
  • Trinity Biotech has been the main confirmatory test provider for the detection of the HIV virus on the African continent over many years.
  • In June 2021, the Company received an update from the WHO on the approval process.
  • Trinity Biotech is at an advanced stage in the development of a SARS-CoV-2 antigen test.

Spearline expands number testing to cover 94% of global GDP

Retrieved on: 
Wednesday, July 14, 2021

The technology company allows global organizations to proactively carry out testing on their numbers and network through an automated Voice Assure platform.

Key Points: 
  • The technology company allows global organizations to proactively carry out testing on their numbers and network through an automated Voice Assure platform.
  • Spearline prides itself on being a customer-centric organization and as such these advancements have been driven by customer requests and core areas of global business operations.
  • Today, Spearline has coverage in over 70 countries globally, covering more than 93.88% of GDP generation.
  • The Spearline platform enables enterprises and telecommunications service providers to test connectivity and audio quality on global telecoms networks, testing automatically at volume.

Iterum Therapeutics Provides Regulatory Update

Retrieved on: 
Thursday, July 1, 2021
Communication, Forward-looking statement, Antibiotic

While we are disappointed by this news, we continue to believe in the potential of sulopenemto help address the growing challenge of antibiotic resistance, said Corey Fishman, Chief Executive Officer of Iterum Therapeutics.

Key Points: 
  • While we are disappointed by this news, we continue to believe in the potential of sulopenemto help address the growing challenge of antibiotic resistance, said Corey Fishman, Chief Executive Officer of Iterum Therapeutics.
  • Iterum Therapeutics is advancing its first compound, sulopenem, a novel penem anti-infective compound, in Phase 3 clinical development with an oral formulation and IV formulation.
  • Iterum Therapeutics has received Qualified Infectious Disease Product (QIDP) and Fast Track designations for its oral and IV formulations of sulopenem in seven indications.
  • Except as required by law, the Company assumes no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future.

Falcon Oil & Gas Ltd. - Commencement of the 2021 Work Programme – Beetaloo Sub-Basin

Retrieved on: 
Tuesday, June 22, 2021
Actuarial science, Articles, Financial risk, Risk, Forward-looking statement

Any statements that are contained in this news release that are not statements of historical fact may be deemed to be forward-looking information.

Key Points: 
  • Any statements that are contained in this news release that are not statements of historical fact may be deemed to be forward-looking information.
  • This information is based on current expectations that are subject to significant risks and uncertainties that are difficult to predict.
  • Readers are cautioned that the foregoing list of important factors is not exhaustive and that these factors and risks are difficult to predict.
  • While encouraging, readers are cautioned not to place reliance on such rates in calculating the aggregate production for Falcon.

PBC Biomed to Collaborate with Curasan AG on Musculoskeletal Regeneration

Retrieved on: 
Tuesday, June 8, 2021
BioMed Central, Medical device, BIOMED, Publishing

SHANNON, Ireland, June 08, 2021 (GLOBE NEWSWIRE) -- PBC Biomed, an Irish-based Medical Device Company, have entered a partnership agreement with curasan AG, a German-headquartered Medical Device company with global distribution, to develop innovative products in the field of musculoskeletal regeneration.

Key Points: 
  • SHANNON, Ireland, June 08, 2021 (GLOBE NEWSWIRE) -- PBC Biomed, an Irish-based Medical Device Company, have entered a partnership agreement with curasan AG, a German-headquartered Medical Device company with global distribution, to develop innovative products in the field of musculoskeletal regeneration.
  • Dirk Dembski, CEO of curasan AG, said Curasans portfolio of products have been appreciated for decades by medical professionals around the globe.
  • When it comes to regeneration of musculoskeletal defects, we are well known for quality, safety, and effectiveness.
  • Paul Burke, Managing Partner at PBC Biomed, said PBC Biomed is delighted to join forces with curasan AG to support their ongoing focus of improving patient healing.

Iterum Therapeutics Provides Update on NDA Review

Retrieved on: 
Thursday, May 27, 2021
Health sciences, Health care, Health, Pharmaceutical industry, Pharmacology, Pharmacy, Prescription Drug User Fee Act, Food and Drug Administration

The review of the NDA is ongoing and the Company was informed that the FDA continues to work toward the PDUFA goal date of July 25, 2021.

Key Points: 
  • The review of the NDA is ongoing and the Company was informed that the FDA continues to work toward the PDUFA goal date of July 25, 2021.
  • Iterum Therapeutics plc is a clinical-stage pharmaceutical company dedicated to developing differentiated anti-infectives aimed at combatting the global crisis of multi-drug resistant pathogens to significantly improve the lives of people affected by serious and life-threatening diseases around the world.
  • Iterum Therapeutics is advancing its first compound, sulopenem, a novel penem anti-infective compound, in Phase 3 clinical development with an oral formulation and IV formulation.
  • Iterum Therapeutics has received Qualified Infectious Disease Product (QIDP) and Fast Track designations for its oral and IV formulations of sulopenem in seven indications.

Falcon Oil & Gas Ltd - Filing of Interim Financial Statements

Retrieved on: 
Thursday, May 27, 2021
Cars, Economy of Alberta, TSX Venture Exchange, Ford Falcon

About Falcon Oil & Gas Ltd.

Key Points: 
  • About Falcon Oil & Gas Ltd.
    Falcon Oil & Gas Ltd is an international oil & gas company engaged in the exploration and development of unconventional oil and gas assets, with the current portfolio focused in Australia, South Africa and Hungary.
  • Falcon Oil & Gas Ltd is incorporated in British Columbia, Canada and headquartered in Dublin, Ireland with a technical team based in Budapest, Hungary.
  • For further information on Falcon Oil & Gas Ltd. please visit www.falconoilandgas.com
    Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
  • Falcon assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those reflected in the forward looking-statements unless and until required by securities laws applicable to Falcon.

Trinity Biotech Announces Results for Q1, 2021

Retrieved on: 
Tuesday, May 25, 2021

Point-of-Care revenues for Q1, 2021 decreased from $3.3m to $1.9m when compared to Q1, 2020, a decrease of 43.4%.

Key Points: 
  • Point-of-Care revenues for Q1, 2021 decreased from $3.3m to $1.9m when compared to Q1, 2020, a decrease of 43.4%.
  • We are seeing evidence of these COVID-19 driven delays abating and it is expected that Point-of-Care revenues will increase as 2021 progresses.
  • Clinical Laboratory revenues increased from $17.8m to $23.7m, which represents an increase of 32.9% compared to Q1, 2020.
  • Gross profit for Q1, 2021 increased from $9.3m to $10.9m when compared to Q1, 2020, a 17.6% increase.